Kancera Crecimiento futuro

Future controles de criterios 5/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Kancera de 47.8% y 40.7%, respectivamente.

Información clave

47.8%

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	45.0%
Tasa de crecimiento de los ingresos	40.7%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	07 Nov 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Previsiones de crecimiento de beneficios e ingresos

OM:KAN - Estimaciones futuras de los analistas y datos financieros pasados (SEK Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	N/A	-15	N/A	N/A	1
12/31/2025	336	284	N/A	284	1
12/31/2024	N/A	-52	N/A	-52	1
6/30/2024	N/A	-53	-51	-51	N/A
3/31/2024	N/A	-60	-51	-51	N/A
12/31/2023	N/A	-65	-56	-56	N/A
9/30/2023	N/A	-60	-52	-52	N/A
6/30/2023	N/A	-61	-58	-58	N/A
3/31/2023	N/A	-58	-57	-57	N/A
12/31/2022	N/A	-52	-48	-48	N/A
9/30/2022	N/A	-51	-53	-53	N/A
6/30/2022	N/A	-52	-50	-50	N/A
3/31/2022	N/A	-49	-44	-44	N/A
12/31/2021	N/A	-46	-44	-44	N/A
9/30/2021	N/A	-45	-41	-41	N/A
6/30/2021	0	-44	-39	-39	N/A
3/31/2021	0	-38	-39	-39	N/A
12/31/2020	0	-40	-39	-39	N/A
9/30/2020	0	-35	-29	-29	N/A
6/30/2020	0	-34	-29	-29	N/A
3/31/2020	0	-40	-36	-36	N/A
12/31/2019	3	-36	-33	-33	N/A
9/30/2019	4	-41	-46	-46	N/A
6/30/2019	3	-44	-53	-53	N/A
3/31/2019	3	-41	-41	-41	N/A
12/31/2018	0	-46	-45	-45	N/A
9/30/2018	0	-46	-50	-50	N/A
6/30/2018	0	-52	-41	-41	N/A
3/31/2018	0	-59	N/A	-54	N/A
12/31/2017	0	-56	N/A	-54	N/A
9/30/2017	0	-51	N/A	-41	N/A
6/30/2017	0	-39	N/A	-40	N/A
3/31/2017	0	-27	N/A	-26	N/A
12/31/2016	0	-22	N/A	-23	N/A
9/30/2016	0	-22	N/A	-22	N/A
6/30/2016	0	-20	N/A	-19	N/A
3/31/2016	0	-20	N/A	-22	N/A
12/31/2015	0	-20	N/A	-21	N/A
9/30/2015	0	-19	N/A	-24	N/A
6/30/2015	0	-18	N/A	-23	N/A
3/31/2015	0	-17	N/A	-21	N/A
12/31/2014	0	-16	N/A	-19	N/A
9/30/2014	2	-13	N/A	-9	N/A
6/30/2014	2	-13	N/A	-9	N/A
3/31/2014	2	-12	N/A	-8	N/A
12/31/2013	2	-7	N/A	-7	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que KAN sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (1.2%).

Beneficios vs. Mercado: Se prevé que KAN sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que KAN sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (40.7% al año) de KAN crezcan más rápidamente que los del mercado Swedish (-0.04% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (40.7% al año) de KAN crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de KAN se prevé que sea elevada dentro de 3 años.

Kancera Crecimiento futuro

Future controles de criterios 5/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Forecast breakeven date pushed back to 2025

Forecast breakeven date moved forward to 2024

Forecast to breakeven in 2025

Recent updates

Chief Executive Officer recently bought kr225k worth of stock

New major risk - Market cap size

Kancera AB (Publ) Announces Chief Medical Officer Changes

Kancera AB (Publ) Provides Operational Update Concerning Its Clinical Development Program

New minor risk - Share price stability

Companies Like Kancera (STO:KAN) Are In A Position To Invest In Growth

Kancera AB's Fractal Study Results to Be Presented at the ESC 2024 Conference

New major risk - Financial position

Kancera AB (publ) Announces Executive Changes

Kancera AB (publ) Reports Positive Results from the Clinical Phase I Study with KAND145 in Healthy Subjects

New major risk - Shareholder dilution

Forecast breakeven date pushed back to 2025

Kancera AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 73.011989 million.

New major risk - Financial position

New major risk - Share price stability

Kancera AB (publ) Reports Positive Top Line Results from the FRACTAL Study

We Think Kancera (STO:KAN) Needs To Drive Business Growth Carefully

Forecast breakeven date moved forward to 2024

Kancera AB (publ), Annual General Meeting, May 27, 2024

Kancera AB (publ) Receives Finnish Regulatory Agency Approval for Phase I Study of KAND145

Kancera AB (publ) Appoints Markus Jerling as Chief Medical Officer

Kancera AB (publ) to Report Q3, 2023 Results on Nov 17, 2023

New major risk - Share price stability

Kancera AB (Publ) Announces Newly Published Research Publication Confirms the Potential for Kancera's Fractalkine Blocker KAND567 in Cardiovascular Disease

Is Kancera (STO:KAN) In A Good Position To Deliver On Growth Plans?

New minor risk - Share price stability

Kancera AB (publ) Reports Dosing of First Patient in the KANDOVA Study

Kancera AB (publ) Appoints Peter Selin as New Chief Executive Officer, Effective from July 1 2023

Independent Director recently sold kr58k worth of stock

Companies Like Kancera (STO:KAN) Are In A Position To Invest In Growth

Forecast to breakeven in 2025

Kancera AB (publ) Submits Regulatory Application to the Swedish Medical Products Agency to Conduct Clinical Studies of KAND567 in Ovarian Cancer

Insufficient new directors

Kancera AB (publ) Reports New Preclinical Results Supporting Potential for Its Ror1 Inhibitor in B-Cell Malignancies

Kancera AB (publ) Reports Promising Preclinical Results from Studies of Its Fractalkine Axis Blocking Drug Candidates in B-Cell Lymphoma

Kancera AB (publ) Reports Good Progress of Recruitment in Ongoing Phase IIa Study of Kand567 in Myocardial Infarction and the Decision to Allow for Recruitment of Additional Patients

Kancera AB (publ) Reports Convincing Preclinical Results and Decision to Initiate Clinical Development of KAND567 in Ovarian Cancer

We Think Kancera (STO:KAN) Can Afford To Drive Business Growth

Insufficient new directors

We're Hopeful That Kancera (STO:KAN) Will Use Its Cash Wisely

Insufficient new directors

Here's Why We're Watching Kancera's (STO:KAN) Cash Burn Situation

First quarter 2021 earnings released: kr0.029 loss per share (vs kr0.56 loss in 1Q 2020)

Insider recently bought kr65k worth of stock

We're Not Very Worried About Kancera's (STO:KAN) Cash Burn Rate

Full year 2020 earnings released: kr0.13 loss per share (vs kr0.18 loss in FY 2019)

New 90-day low: kr1.62

Here's Why We're Not Too Worried About Kancera's (STO:KAN) Cash Burn Situation

New 90-day low: kr2.23

New 90-day low: kr2.37

Kancera AB (publ) to Report Q3, 2021 Results on Nov 19, 2021

New 90-day high: kr3.98

First half earnings released

New 90-day high - kr2.96

Oncopeptides AB (publ) (OM:ONCO) agreed to acquire Kancera's drug development facility in Solna, Sweden.

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento